Cited by 261Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchTreatment of Major Depression

The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Kinon, Bruce J., Zhang, Lu, Millen, Brian A., Osuntokun, Olawale O., Williams, Judy E., Kollack-Walker, Sara, Jackson, Kimberley, Kryzhanovskaya, Ludmila, Jarkova, Natalia·2011·Journal of Clinical Psychopharmacology

DOI 10.1097/jcp.0b013e318218dcd5

Open this paper in CoChat — free account

Abstract

The primary objective of this study was to test the hypothesis that 1 or more dose levels of LY2140023 monohydrate, an oral prodrug of the potent metabotropic glutamate (mGlu) 2/3 receptor agonist LY404039, given to patients with schizophrenia for 4 weeks would demonstrate significantly greater efficacy than placebo. The HBBI study was a multicenter, randomized, double-blind, parallel, placebo- and active-controlled trial. Male and female patients aged 18 to 65 years who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia were randomized in a 2:2:2:2:2:1 ratio to receive 5-, 20-, 40-, or 80-mg LY2140023 monohydrate twice daily, placebo twice daily, or placebo (am) and 15 mg of olanzapine (pm) daily. Efficacy was defined as the change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score assessed at 4 weeks. The primary analysis did not show that any of the 4 LY2140023 monohydrate doses were more efficacious than placebo as measured by the PANSS total score. Similarly, olanzapine did not significantly separate from placebo. A higher-than-anticipated treatment effect (14.6-point improvement) in the placebo group was observed on PANSS total score. LY2140023 monohydrate was generally well tolerated, although 4 patients reported the serious adverse event of convulsion. LY2140023 monohydrate-treated patients showed little change in dopamine-related adverse events and weight. The results of the HBBI study are considered to be inconclusive because LY2140023 monohydrate and the active control olanzapine did not separate from placebo in the treatment of patients with acutely exacerbated schizophrenia. Additional efficacy, safety, and tolerability testing are needed.

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318218dcd5

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,097
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Self-citation
Research diagnoses for tardive dyskinesia.
Schooler, N. R., & Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040080014 · Cited by 951
What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
Kemp, A. S., Schooler, N. R., Kalali, A. H., Alphs, L. D., Anand, R., Awad, G. A., Davidson, M., Dubé, S., Ereshefsky, L., Gharabawi, G. M., et al. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn110 · Cited by 151
Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?
Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100
Translational research in central nervous system drug discovery
Hurko, O., & Ryan, J. L. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.671 · Cited by 96

Flagged first, then by citations

Show all 15 references

1 of the 15 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 261

Metabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review
Matrisciano, F., Panaccione, I., Grayson, D. R., Nicoletti, F., & Guidotti, A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150713174242 · Cited by 31
Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction
Cross, A. J., Anthenelli, R. M., & Li, X. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.021 · Cited by 31
Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990–2014
Gargiulo, P. Á., & de Gargiulo, A. I. L. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.03.010 · Cited by 33
Using human brain imaging studies as a guide toward animal models of schizophrenia
Bolkan, S. S., Poyraz, F. C., & Kellendonk, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.055 · Cited by 33
The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice
Ago, Y., Araki, R., Yano, K., Kawasaki, T., Chaki, S., Nakazato, A., Onoe, H., Hashimoto, H., Baba, A., Takuma, K., et al. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11200sc · Cited by 29
Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction
Oosterlaken, M., Rogliardo, A., Lipina, T. V., Lafon, P., Tsitokana, M. E., Keck, M., Cahuzac, H., Prieu-Sérandon, P., Diem, S., Derieux, C., et al. (2025) · Nature · doi:10.1038/s41586-025-09265-8 · Cited by 31
Preclinical models of antipsychotic drug action
Moreno, J. L., & González‐Maeso, J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000606 · Cited by 28
mGlu5-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia
Wierońska, J. M., Kłeczek, N., Woźniak, M., Gruca, P., Łasoń, M., Papp, M., Brański, P., Burnat, G., & Pilc, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.03.010 · Cited by 30
Targeting glutamate to treat schizophrenia: lessons from recent clinical studies
Beck, K., Javitt, D. C., & Howes, O. D. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4318-6 · Cited by 29
Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1S,2S,4S,5R,6S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3Receptor Agonist
Monn, J. A., Henry, S. S., Massey, S. M., Clawson, D. K., Chen, Q., Diseroad, B. A., Bhardwaj, R. M., Atwell, S., Lu, F., Wang, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01481 · Cited by 29
Target selection for deep brain stimulation in treatment resistant schizophrenia
Corripio, I., Roldán, A., McKenna, P. J., Sarró, S., Alonso-Solís, A., Salgado, L., Álvarez, E., Molet, J., Pomarol‐Clotet, E., & Portella, M. J. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110436 · Cited by 33
Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR
Sanger, H., Hanna, L., Colvin, E. M., Grubisha, O., Ursu, D., Heinz, B. A., Findlay, J. D., Vivier, R. G., Sher, E., Lodge, D., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.023 · Cited by 29
mGluR2 positive allosteric modulators: an updated patent review (2013–2018)
Trabanco, A. A., Bartolomé, J. M., & Cid, J. M. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1637421 · Cited by 29
NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test
Janczura, K. J., Olszewski, R. T., Bzdega, T., Bacich, D. J., Heston, W. D. W., & Neale, J. H. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.027 · Cited by 28
Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 – present)
Célanire, S., Sebhat, I. K., Wichmann, J., Mayer, S., Schann, S., & Gatti, S. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.983899 · Cited by 28
Involvement of GABABReceptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4Receptor, LSP4-2022
Woźniak, M., Acher, F., Marciniak, M., Łasoń, M., Gruca, P., Papp, M., Pilc, A., & Wierońska, J. M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150516000630 · Cited by 28
The NIMH ‘Fast-Fail Trials’ (FAST) Initiative: Rationale, Promise, and Progress
Grabb, M. C., Hillefors, M., & Potter, W. Z. (2020) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00343-y · Cited by 28
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Veselinović, T., & Neuner, I. (2022) · CNS Drugs · doi:10.1007/s40263-022-00935-z · Cited by 31
Antipsychotic treatment modulates glutamate transport and NMDA receptor expression
Zink, M., Englisch, S., & Schmitt, A. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0534-4 · Cited by 27
Newer antipsychotics and upcoming molecules for schizophrenia
George, M., Amrutheshwar, R., Rajkumar, R. P., Kattimani, S., & Dkhar, S. A. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1498-4 · Cited by 26
Schizophrenia: Antipsychotics and drug development
Remington, G. J., Hahn, M., Agarwal, S. M., Chintoh, A. F., & Agid, O. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113507 · Cited by 30
Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance
Neumeier, M. S., Homan, S., Vetter, S., Seifritz, E., Kane, J. M., Huhn, M., Leucht, S., & Homan, P. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab078 · Cited by 24
Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics
MacKay, M.-A. B., Paylor, J. W., Wong, J. T. F., Winship, I. R., Baker, G. B., & Dursun, S. M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00537 · Cited by 27
When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia
Papanastasiou, E., Stone, J. M., & Shergill, S. S. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.110999 · Cited by 24
The mGluR 2/3 agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence, but not working memory impairments, in mice
Sokolenko, E., Hudson, M. R., Nithianantharajah, J., & Jones, N. C. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119875976 · Cited by 24
Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
Wu, Q., Huang, J., & Wu, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.641047 · Cited by 24
Alternative pharmacologic targets for the treatment of schizophrenia
Miyamoto, S., Jarskog, L. F., & Fleischhacker, W. W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835d8296 · Cited by 23
Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders
Wierońska, J. M., & Pilc, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.010 · Cited by 23
A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
Geerts, H., Roberts, P., & Spiros, Ä. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.12 · Cited by 23
Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice
Cieślik, P., Radulska, A., Pelikant‐Małecka, I., Płoska, A., Kalinowski, L., & Wierońska, J. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112781 · Cited by 23
Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond
Koola, M. M. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2758 · Cited by 23
A Quantitative Systems Pharmacology Computer Model for Schizophrenia Efficacy and Extrapyramidal Side Effects
Spiros, Ä., Roberts, P., & Geerts, H. (2012) · Drug Development Research · doi:10.1002/ddr.21008 · Cited by 22
QSAR design of triazolopyridine mGlu2 receptor positive allosteric modulators
Tresadern, G., Cid, J. M., & Trabanco, A. A. (2014) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2014.07.006 · Cited by 21
Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen
Halberstadt, A. L., van der Zee, J. V. F., Chatha, M., Geyer, M. A., & Powell, S. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5118-y · Cited by 21
Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia
Wolf, D. H., Zheng, D., Kohler, C. G., Turetsky, B. I., Ruparel, K., Satterthwaite, T. D., Elliott, M. A., March, M. E., Cross, A. J., Smith, M. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01320-w · Cited by 19
Negative schizophrenic symptoms as prefrontal cortex dysfunction: Examination using a task measuring goal neglect
Fuentes‐Claramonte, P., Ramiro, N., Torres, L., Argila‐Plaza, I., Salgado‐Pineda, P., Soler‐Vidal, J., García‐León, M. Á., Albacete, À., Bosque, C., Panicali, F., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103119 · Cited by 19
Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects
Ibi, D. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173474 · Cited by 21
Psychopharmacological Treatment of Neurocognitive Deficits in People with Schizophrenia: A Review of Old and New Targets
Ahmed, A. O., & Bhat, I. (2014) · CNS Drugs · doi:10.1007/s40263-014-0146-6 · Cited by 20
Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia
Li, M. S., Gulchina, Y., Monaco, S. A., Xing, B., Ferguson, B. R., Li, Y., Li, F., Hu, X., & Gao, W. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.02.004 · Cited by 19
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
Nisenbaum, L., Downing, A. M., Zhao, F., Millen, B. A., Munsie, L. M., Kinon, B. J., Adams, D. H., Gomez, J., & Penny, M. A. (2016) · Journal of Personalized Medicine · doi:10.3390/jpm6010009 · Cited by 18
Self-citation
Simultaneous activation of mGlu2 and muscarinic receptors reverses MK-801-induced cognitive decline in rodents
Cieślik, P., Domin, H., Chocyk, A., Gruca, P., Litwa, E., Płoska, A., Radulska, A., Pelikant‐Małecka, I., Brański, P., Kalinowski, L., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107866 · Cited by 18
DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation
Wischhof, L., Aho, H. E. A., & Koch, M. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.011 · Cited by 17
Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression
Wood, C. M., Wafford, K. A., McCarthy, A. P., Hewes, N., Shanks, E., Lodge, D., & Robinson, E. S. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.07.013 · Cited by 18
Glutamate modulators for treatment of schizophrenia
Zhand, N., Attwood, D. G., & Harvey, P. D. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.02.001 · Cited by 16
The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework
Martins, R., Kadakia, A., Williams, G. R., Milanovic, S. M., & Connolly, M. P. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14746 · Cited by 15
Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Olivares-Berjaga, D., Martínez-Pinteño, A., Rodríguez, N., Mas, S., Morén, C., Parellada, E., & Gassó, P. (2025) · Translational Psychiatry · doi:10.1038/s41398-024-03194-2 · Cited by 12
Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men
Ahnaou, A., de Boer, P., Lavreysen, H., Huysmans, H., Sinha, V., Raeymaekers, L., de Casteele, T. V., Cid, J. M., Nueten, L. V., Macdonald, G. J., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.11.031 · Cited by 15
Imaging as Tool to Investigate Psychoses and Antipsychotics
Booij, J., & van Amelsvoort, T. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_12 · Cited by 14
The impact of genetics on future drug discovery in schizophrenia
Matsumoto, M., Walton, N. M., Yamada, H., Kondo, Y., Marek, G. J., & Tajinda, K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1324419 · Cited by 13
Cognitive therapy: at last an alternative to antipsychotics?
Howes, O. D. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62569-6 · Cited by 13
Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects
Watanabe, M., Marcy, B., Kinoshita, K., Fukasawa, M., Hikichi, H., Chaki, S., Okuyama, S., Gevorkyan, H., & Yoshida, S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14331 · Cited by 13
In the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors
Dedeurwaerdere, S., Boets, S., Janssens, P., Lavreysen, H., & Steckler, T. (2014) · Acta Neurologica Belgica · doi:10.1007/s13760-014-0407-7 · Cited by 13
Neuronal activity patterns in the mediodorsal thalamus and related cognitive circuits are modulated by metabotropic glutamate receptors
Copeland, C. S., Neale, S. A., & Salt, T. E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.031 · Cited by 13
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
Huang, M. W., Gibson, R. C., Jayaram, M., & Caroff, S. N. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013100.pub2 · Cited by 14
Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery
Cieślik, P., & Wierońska, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228811 · Cited by 12
IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
Moran, P. M., & Granger, K. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107727 · Cited by 13
Meta-analysis of Dropout Rates in Placebo-Controlled Randomized Clinical Trials of Atypical Antipsychotics Assessed by PANSS
Matsusaki, A., Kaneko, M., & Narukawa, M. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00813-5 · Cited by 11
Activation of Metabotropic Glutamate Receptor (mGlu2) and Muscarinic Receptors (M1, M4, and M5), Alone or in Combination, and Its Impact on the Acquisition and Retention of Learning in the Morris Water Maze, NMDA Expression and cGMP Synthesis
Wierońska, J. M., Cieślik, P., Burnat, G., & Kalinowski, L. (2023) · Biomolecules · doi:10.3390/biom13071064 · Cited by 11
A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia
Stauffer, V. L., Baygani, S., Kinon, B. J., & Krikke-Workel, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000187 · Cited by 11
Self-citation
Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank
Dean, B., Möller, H., Svensson, T. H., Geyer, M. A., Rujescu, D., Scarr, E., & Millan, M. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001077 · Cited by 11
Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia
Citrome, L. (2012) · CNS Spectrums · doi:10.1017/s1092852912000727 · Cited by 10
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740
Orlando, R., Borro, M., Motolese, M., Molinaro, G., Scaccianoce, S., Caruso, A., di Nuzzo, L., Caraci, F., Matrisciano, F., Pittaluga, A., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.009 · Cited by 10
The quality of reporting of phase II and III trials for new antipsychotics: a systematic review
Patel, M. X., Collins, S., Hellier, J. M., Bhatia, G., & Murray, R. M. (2014) · Psychological Medicine · doi:10.1017/s0033291714001214 · Cited by 9
The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions
Abbs, B., Achalia, R. M., Adelufosi, A. O., Aktener, A. Y., Beveridge, N. J., Bhakta, S. G., Blackman, R. K., Bora, E., Byun, M. S., Cabanis, M., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.024 · Cited by 8
Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis
Layton, M. E., Reif, A. J., Hartingh, T. J., Rodzinak, K. J., Dudkin, V., Wang, C., Arrington, K. L., Kelly, M. J., Garbaccio, R. M., O’Brien, J. A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.021 · Cited by 9
Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment
O’Tuathaigh, C. M. P., Desbonnet, L., & Waddington, J. L. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_5 · Cited by 8
An agonist at glutamate and dopamine D2 receptors, LY404039
Seeman, P. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.001 · Cited by 8
The Impact of LY487379 or CDPPB on eNOS Expression in the Mouse Brain and the Effect of Joint Administration of Compounds with NO• Releasers on MK-801- or Scopolamine-Driven Cognitive Dysfunction in Mice
Płoska, A., Siekierzycka, A., Cieślik, P., Dobrucki, L. W., Kalinowski, L., & Wierońska, J. M. (2024) · Molecules · doi:10.3390/molecules29030627 · Cited by 7
Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.
St, S., Bj, K., Brannan, S. K., Ak, K., van Gerven, J., Mahableshwarkar, A. R., & Gs, S. (2015) · Europe PMC (PubMed Central) · Cited by 7
Insights into the Structural Aspects of the mGlu Receptor Orthosteric Binding Site
Hao, J., & Chen, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011094935 · Cited by 6
mGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats
Megens, A. A. H. P., Hendrickx, H. M. R., Hens, K. A., Talloen, W., & Lavreysen, H. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.044 · Cited by 7
Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials
Rao, N. P., & Remington, G. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873790 · Cited by 8
Recommendations for the treatment of schizophrenia with negative symptoms. Standards of pharmacotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 1
Szulc, A., Samochowiec, J., Gałecki, P., Wojnar, M., Heitzman, J., & Dudek, D. (2019) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/100698 · Cited by 7
Comment on “A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia” by Kinon et al
Seeman, P. M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318248daaa · Cited by 7
The mGlu7 receptor in schizophrenia - An update and future perspectives
Cieślik, P., & Wierońska, J. M. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173430 · Cited by 6
mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
Célanire, S., Duvey, G., Poli, S. M., & Rocher, J. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00006-0 · Cited by 7
Metabotropic Glutamate Receptor 2 Activators
Cid, J. M., Trabanco, A. A., & Lavreysen, H. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_48 · Cited by 6
Schizophrenia Pharmacology: Past, Present, and Future Targets for Intervention
Cronenwett, W. J. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160009 · Cited by 7
Epigenetic regulation of metabotropic glutamate 2/3 receptors: Potential role for ultra-resistant schizophrenia?
Matrisciano, F. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173589 · Cited by 6
Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy
McKenna, P. J., & Mortimer, A. M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.864237 · Cited by 6
Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis
AbouShawareb, H., Abbas, O., Ghabour, H., Hassan, O., Shelbaya, A. N., Abdelsalam, R., & Meshref, M. M. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07199-z · Cited by 5
The impact of mGlu2 or mGlu5 receptor activators on the production of l-arginine derivatives and the expression of PRMT5 or DDAH1 enzymes in animal models of cognitive decline
Płoska, A., Radulska, A., Siekierzycka, A., Cieślik, P., Santocki, M., Dobrucki, I. T., Kalinowski, L., & Wierońska, J. M. (2024) · Nitric Oxide · doi:10.1016/j.niox.2024.11.010 · Cited by 5
Delusions: Understanding the Un-understandable
McKenna, P. J. (2017) · Cited by 6
Positive allosteric modulators (PAMs) of the group II metabotropic glutamate receptors: Design, synthesis, and evaluation as ex-vivo tool compounds
Yamada, Y., Gilliland, K. M., Xiang, Z., Haymer, D. H., Crocker, K. E., Loch, M. T., Schulte, M. I., Rodriguez, A. L., Niswender, C. M., Conn, P. J., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128342 · Cited by 5
Onset of Action of Selected Second-Generation Antipsychotics (Pines)–A Systematic Review and Meta-Analyses
Meyer, R., Skov, K., Dhillon, I. K., Olsson, E., Graudal, N. A., Baandrup, L., & Jűrgens, G. (2022) · Biomedicines · doi:10.3390/biomedicines11010082 · Cited by 5
Schizophrenia in the 21st Century
Burne, T. H. J. (2012) · InTech eBooks · doi:10.5772/1669 · Cited by 5
Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data
Matsusaki, A., Kaneko, M., & Narukawa, M. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0661-1 · Cited by 5
Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia
Marek, G. J., Kinon, B. J., McKinzie, D. L., Schkeryantz, J. M., & Monn, J. A. (2012) · doi:10.1002/9781118309421.ch6 · Cited by 5
Self-citation
Metabotropic glutamate receptors and cognition: From underlying plasticity and neuroprotection to cognitive disorders and therapeutic targets
Hoglund, B. K., Carfagno, V. F., Olive, M. F., & Leyrer‐Jackson, J. M. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.10.004 · Cited by 4
The Impact of Aberrant Data Variability on Drug–Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical Trial
Kott, A., Brannan, S. K., Wang, X., & Daniel, D. G. (2021) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgab037 · Cited by 4
Antipsychotic Dosing: Extended, and Transient
Seeman, P. M., & Remington, G. J. (2012) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.6.2.6 · Cited by 4
Therapeutic Considerations in Individuals at Clinical Risk for Developing Psychosis
Singh, F., DeJoseph, M. L., & Cadenhead, K. S. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0009-2 · Cited by 4
Adverse Events in Healthy Subjects Exposed to Single and Multiple Doses of LY2140023 Monohydrate
Ayan‐Oshodi, M., Wondmagegnehu, E. T., Lowe, S. L., Kryzhanovskaya, L. A., Walker, D. J., & Kinon, B. J. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182542633 · Cited by 4
Self-citation
Identifying drug targets for schizophrenia through gene prioritizationPreprint
Kraft, J., Braun, A., Awasthi, S., Panagiotaropoulou, G., Schipper, M., Bell, N. Y., Posthuma, D., Pardiñas, A. F., Ripke, S., & Heilbron, K. (2024) · medRxiv · doi:10.1101/2024.05.15.24307423 · Cited by 4
The need to incorporate polysubstance use in neuropsychopharmacology research: Biological lessons and new opportunities
Joffe, M. E., Ferguson, S. M., Gilpin, N. W., Herman, M. A., Knackstedt, L. A., Randall, P. A., Schindler, A. G., Torregrossa, M. M., & Rinker, J. A. (2025) · Addiction Neuroscience · doi:10.1016/j.addicn.2025.100246 · Cited by 3
Response efficacy and heterogeneity of antipsychotic drugs in schizophrenia: Systemic review and meta‐analysis
Zhang, X., Tang, J. Z., Zhang, X., Abdelrahim, M. E. A., & Yin, Z. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2808 · Cited by 3
Antipsychotika abseits der Dopamin-D2-Blockade – Xanomelin-Trospium als Hoffnungsträger?
Paulzen, M., & Kuhn, J. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01830-w · Cited by 3
Developing tomorrow's antipsychotics: the need for a more personalised approach
Hunter, R. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.110.008235 · Cited by 3
Effects of the PAM of mGluR2, JNJ-46356479, on brain apoptotic protein levels in a mouse model of schizophrenia
Olivares-Berjaga, D., Martínez-Pinteño, A., Rodríguez, N., Madero, S., Prohens, L., Martínez-Serrano, I., Mas, S., Morén, C., Parellada, E., & Gassó, P. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110955 · Cited by 3
Acute Management of Schizophrenia
Janicak, P. G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0656-7_7 · Cited by 3

Authors: Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N.
Affiliations: Eli Lilly (United States) (US)
Corresponding author: Kinon, Bruce J.
Zhang, Lu
Millen, Brian A.
Osuntokun, Olawale O.
Williams, Judy E.
Jackson, Kimberley
Kryzhanovskaya, Ludmila
ORCID: Millen, Brian A.
Jackson, Kimberley
Venue: Journal of Clinical Psychopharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-06
Volume: 31
Issue: 3
Pages: 349-355
ISSN: 0271-0749 (ISSN-L)
DOI: 10.1097/jcp.0b013e318218dcd5
OpenAlex: W2312770619
Cited by: 256
References: 15
Citations by year: 2026: 5 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 17 · 2021: 9 · 2020: 10 · 2019: 13 · 2018: 12 · 2017: 13 · 2016: 19 · 2015: 28 · 2014: 29 · 2013: 34 · 2012: 39
FWCI: 24.04
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: prodrugs, schizophrenia, acute exacerbation of schizophrenia, olanzapine, dose-ranging, PANSS, convulsions, weight change, drug safety and tolerability
MeSH terms: Olanzapine, Assessment of Medication Adherence, Adolescent, Adult, Aged, Amino Acids, Benzodiazepines, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Inpatients, Male, Middle Aged, Prodrugs, Psychiatric Status Rating Scales, Schizophrenia, Antipsychotic Agents, Drug Monitoring, Receptors, Metabotropic Glutamate, Diagnostic and Statistical Manual of Mental Disorders, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks